Investigational Drug Information for ampreloxetine
✉ Email this page to a colleague
What is the drug development status for ampreloxetine?
ampreloxetine is an investigational drug.
There have been 6 clinical trials for ampreloxetine.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 22nd 2019.
The most common disease conditions in clinical trials are Hypotension, Orthostatic, Hypotension, and Pure Autonomic Failure. The leading clinical trial sponsors are Theravance Biopharma and [disabled in preview].
There are eighteen US patents protecting this investigational drug and one hundred and eighteen international patents.
Summary for ampreloxetine
| US Patents | 18 |
| International Patents | 118 |
| US Patent Applications | 46 |
| WIPO Patent Applications | 7 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 3 (2019-02-22) |
| Vendors | 15 |
Recent Clinical Trials for ampreloxetine
| Title | Sponsor | Phase |
|---|---|---|
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy | Theravance Biopharma | Phase 3 |
| Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects | Theravance Biopharma | Phase 1 |
| Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855 | Theravance Biopharma | Phase 1 |
Clinical Trial Summary for ampreloxetine
Top disease conditions for ampreloxetine
Top clinical trial sponsors for ampreloxetine
US Patents for ampreloxetine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ampreloxetine | ⤷ Sign Up | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | ⤷ Sign Up |
| ampreloxetine | ⤷ Sign Up | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | ⤷ Sign Up |
| ampreloxetine | ⤷ Sign Up | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | ⤷ Sign Up |
| ampreloxetine | ⤷ Sign Up | Methods for treating neurogenic orthostatic hypotension | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | ⤷ Sign Up |
| ampreloxetine | ⤷ Sign Up | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | ⤷ Sign Up |
| ampreloxetine | ⤷ Sign Up | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | Theravance Biopharma R&D IP, LLC (South San Francisco, CA) | ⤷ Sign Up |
| ampreloxetine | ⤷ Sign Up | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ampreloxetine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ampreloxetine | Argentina | AR074128 | 2028-11-14 | ⤷ Sign Up |
| ampreloxetine | Argentina | AR074350 | 2028-11-14 | ⤷ Sign Up |
| ampreloxetine | Argentina | AR114965 | 2028-11-14 | ⤷ Sign Up |
| ampreloxetine | Australia | AU2009313948 | 2028-11-14 | ⤷ Sign Up |
| ampreloxetine | Australia | AU2009313949 | 2028-11-14 | ⤷ Sign Up |
| ampreloxetine | Australia | AU2009313951 | 2028-11-14 | ⤷ Sign Up |
| ampreloxetine | Brazil | BRPI0921593 | 2028-11-14 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
